卡麦角林通过增强乳腺复旧抑制产后乳腺癌并与年轻女性风险降低相关
该研究在小鼠模型中证实,哺乳后单次给予多巴胺激动剂卡麦角林可延迟并减少Brca1突变小鼠产后乳腺癌发生,机制与增强乳腺复旧、减少导管面积和增殖、逆转T细胞耗竭相关。两项欧洲女性回顾性队列显示卡麦角林治疗与产后乳腺癌发生率降低相关,荟萃分析提示风险约降低69%。
要点
- 哺乳后单次卡麦角林可延迟并降低Brca1突变小鼠产后乳腺癌发生
- 卡麦角林增强乳腺复旧、减少导管面积与增殖并逆转T细胞耗竭
- 欧洲两大队列回顾性研究提示卡麦角林与产后乳腺癌风险降低相关
核心结论
- 卡麦角林可能作为靶向产后乳腺复旧的新型低风险化学预防策略。
研究设计与样本
- K14-Cre; Brca1F/F, Trp53F/F小鼠哺乳后单次给予卡麦角林,观察产后乳腺癌发生。
- 两项欧洲女性大型队列的独立回顾性研究及荟萃分析评估卡麦角林与产后乳腺癌风险的关联。
主要发现
- 卡麦角林延迟并减少Brca1突变小鼠产后乳腺肿瘤发生。
- 卡麦角林重塑乳腺:增强复旧、减少导管面积和增殖、逆转T细胞耗竭,可能通过调节离子通道表达。
- 两项欧洲女性队列显示卡麦角林治疗与产后乳腺癌发生率降低相关,荟萃分析提示风险约降低69%。
关键数值与推荐
- 荟萃分析提示卡麦角林治疗与产后乳腺癌风险约降低69%相关。
临床怎么用
- 对于高风险女性,产后靶向乳腺复旧可能成为化学预防新方向。
- 卡麦角林作为低风险化学预防策略值得进一步前瞻性验证。
局限性
- 人类证据来自回顾性队列研究,非随机对照试验。
- 机制研究主要基于Brca1突变小鼠模型。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Breast cancer that arises in the postpartum period often carries a poor prognosis and urgently requires chemoprevention strategies, particularly for women at elevated risk. Here, we report that a single post-lactation dose of cabergoline, a dopaminergic agonist that blocks prolactin secretion, delays the onset and reduces the incidence of postpartum mammary cancer in K14-Cre; Brca1F/F, Trp53F/F mice. In these mice, cabergoline treatment remodels the mammary gland by potentiating involution, reducing ductal area and proliferation, and reversing T cell exhaustion, potentially through modulation of ion channel expression. Notably, independent retrospective studies in two large cohorts of European women showed that cabergoline treatment was associated with a lower incidence of postpartum breast cancer, with a meta-analysis indicating an approximate 69% reduction in risk. Our work underscores the importance of targeting postlactational involution as a strategy for the prevention of postpartum breast cancer and positions cabergoline as a novel, low-risk chemoprevention strategy.
引用
- García-Sancha N, Corchado-Cobos R, Ghorayeb R, et al. Cabergoline Suppresses Postpartum Breast Cancer by Enhancing Mammary Gland Involution in Brca1-Mutant Mice and Is Associated with Reduced Risk in Younger Women. Cancer Discov. 2026. PMID: 42878664. doi:10.1158/2159-8290.CD-26-0187
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。